drugset / Trial / NCT05106335
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.
Timeline
- Start
- 2022-01-06
- Primary completion
- 2022-05-11
- Completion
- 2022-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | Intravenous |
| Comparator | Docetaxel | Small molecule | — | Intravenous |
| Subject | Famitinib | Small molecule | — | Oral |